Tanvex BioPharma Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	878.71	376.96	380.75	786.23	2,223
Cash & Short-Term Investments	878.71	376.96	380.75	786.23	2,223
Cash Growth	133.11%	-1.00%	-51.57%	-64.63%	7.46%
Accounts Receivable	67.32	0.07	9.4	0.33	2.52
Other Receivables	89.3	31.58	27.43	27.36	25.31
Receivables	156.62	31.65	36.83	27.69	27.84
Inventory	416.48	217.84	108.29	170.84	90.33
Prepaid Expenses	44.32	49.18	78.35	58.95	60.85
Other Current Assets	1.06	-	-	-	-
Total Current Assets	1,497	675.62	604.21	1,044	2,402
Property, Plant & Equipment	2,761	1,827	1,928	2,151	2,114
Goodwill	2,910	-	-	-	-
Other Intangible Assets	485.32	7.07	3.38	12.07	10.17
Long-Term Deferred Tax Assets	6.34	-	-	-	-
Other Long-Term Assets	301.22	225.3	227.67	213.47	187.58
Total Assets	7,961	2,735	2,763	3,420	4,714
Accounts Payable	102.99	-	-	-	-
Accrued Expenses	147.64	134.27	-	115.93	137.49
Short-Term Debt	30	-	-	-	-
Current Portion of Leases	181.63	160.01	163.45	124.65	88.75
Current Income Taxes Payable	26.89	-	-	-	-
Current Unearned Revenue	79.3	11.11	6.91	28.07	-
Other Current Liabilities	231.21	42.75	193.38	34.63	22.28
Total Current Liabilities	799.66	348.14	363.73	303.29	248.51
Long-Term Leases	1,367	1,488	1,568	1,715	1,670
Long-Term Unearned Revenue	99	5.47	10.23	-	-
Other Long-Term Liabilities	1.72	-	-	10.47	-
Total Liabilities	2,267	1,842	1,942	2,028	1,919
Common Stock	2,649	1,641	1,340	3,527	3,525
Additional Paid-In Capital	18,906	13,567	12,431	11,061	10,988
Retained Earnings	-15,637	-14,136	-12,755	-12,969	-11,327
Comprehensive Income & Other	-223.63	-177.94	-194.17	-227.09	-390.12
Shareholders' Equity	5,694	893.31	821.11	1,391	2,795
Total Liabilities & Equity	7,961	2,735	2,763	3,420	4,714
Total Debt	1,578	1,648	1,732	1,839	1,759
Net Cash (Debt)	-699.69	-1,271	-1,351	-1,053	463.95
Net Cash Growth	-	-	-	-	-15.52%
Net Cash Per Share	-2.86	-8.19	-10.48	-8.95	4.27
Filing Date Shares Outstanding	264.86	164.07	133.96	117.64	117.57
Total Common Shares Outstanding	264.86	164.07	133.96	117.64	117.57
Working Capital	697.52	327.48	240.48	740.43	2,153
Book Value Per Share	21.50	5.44	6.13	11.83	23.77
Tangible Book Value	2,298	886.24	817.73	1,379	2,785
Tangible Book Value Per Share	8.68	5.40	6.10	11.73	23.68
Machinery	1,126	1,089	982.54	975.18	889.53
Construction In Progress	849.55	44.34	83.71	72.82	53.8
Leasehold Improvements	517.23	509.94	415.69	388.62	318.95

Source: S&P Global Market Intelligence. Standard template. Financial Sources.